• Pentoxifylline Suppresses Macrophage Activation via cAMP Mod

  2026-05-09

  This study systematically demonstrates that pentoxifylline, a non-specific phosphodiesterase inhibitor, suppresses macrophage activation and nitric oxide production both in vitro and in vivo by elevating intracellular cAMP. These findings clarify the mechanistic basis for pentoxifylline’s anti-inflammatory and immunomodulatory roles, informing research into NO-mediated inflammatory disorders.

• S63845 MCL1 Inhibitor: Precision Apoptosis in Cancer Models

  2026-05-08

  S63845 is a potent, selective MCL1 inhibitor that enables targeted activation of the mitochondrial apoptotic pathway in hematological cancer research. Its nanomolar affinity and BAX/BAK-dependent mechanism distinguish it as a reference tool for dissecting apoptosis resistance and evaluating combinatorial senolytic strategies.

• Nonconventional Agonist-Antagonist Dynamics at the GLP-1 Rec

  2026-05-08

  Chepurny et al. (2019) reveal that glucagon, traditionally considered a selective agonist for its own receptor, can act as a nonconventional agonist at the GLP-1 receptor—a finding uncovered through high-throughput FRET cAMP assays. Their work challenges assumptions about peptide ligand selectivity at GPCRs and provides important methodological and conceptual advances for metabolic and type 2 diabetes research.

• Catalpol in Mitochondrial Metabolism and Liver Injury Models

  2026-05-07

  Explore how Catalpol, a natural iridoid glycoside, uniquely modulates mitochondrial metabolism and SIRT1/HIF-1α signaling to mitigate drug-induced liver injury. This article provides advanced mechanistic insight and actionable guidance for liver fibrosis and metabolic research applications.

• KN-62, 1-[N,O-bis-(5-isoquinolinesulphonyl)-N-methyl-L-tyros

  2026-05-07

  This article unpacks real-world laboratory challenges in calcium signaling and cell cycle research, demonstrating how KN-62, 1-[N,O-bis-(5-isoquinolinesulphonyl)-N-methyl-L-tyrosy]-4-phenylpiperazine (SKU A8180) from APExBIO provides reproducible, evidence-based solutions. Scenario-driven Q&A blocks offer practical protocols, troubleshooting, and product comparison to optimize cell viability, proliferation, and cytotoxicity workflows.

• Moesin as a Biomarker of Endothelial Injury in Sepsis: Insig

  2026-05-06

  The reference study identifies moesin (MSN) as a novel and quantifiable biomarker of endothelial injury during sepsis, connecting its serum levels with severity markers and functional endothelial disruption. These findings illuminate new directions for mechanistic research in vascular permeability and inflammation, providing a technical foundation for translational model design.

• Tomentodione M Reverses MDR by Targeting P-gp via p38 MAPK I

  2026-05-06

  This study demonstrates that tomentodione M (TTM), a natural meroterpenoid, sensitizes multidrug-resistant cancer cells to chemotherapeutic agents by downregulating P-glycoprotein through inhibition of p38 MAPK signaling. Findings support TTM as a mechanistically distinct and promising modulator of drug resistance, with implications for optimizing cancer chemotherapy research and apoptosis studies.

• Azathramycin A: Translational Leverage in TB Research Models

  2026-05-05

  This article examines the mechanistic and strategic advantages of Azathramycin A, a macrolide antibiotic and ribosome binder, for translational tuberculosis (TB) research. By weaving together molecular insights, experimental best practices, competitive context, and guidance on reproducibility, the piece aims to empower researchers to tackle persistent bottlenecks in Mycobacterium tuberculosis infection models and antibiotic resistance investigations. The discussion leverages recent benchmarking studies, protocol parameters, and cross-asset analysis to position Azathramycin A as an advanced, workflow-optimized tool for next-generation antibacterial agent discovery.

• Recombinant Human Growth Hormone (GH): Data-Driven Solutions

  2026-05-05

  This article addresses real laboratory challenges in cell viability and proliferation assays, showcasing how Recombinant Human Growth Hormone (GH) (SKU P1223) delivers reproducible, high-sensitivity results for growth hormone signaling studies. Grounded in recent literature and quantitative benchmarks, it guides researchers in optimizing protocols and making reliable product choices.

• KN-62 and CaMKII: Uncovering Mechanistic Precision in Calciu

  2026-05-04

  Explore how KN-62, 1-[N,O-bis-(5-isoquinolinesulphonyl)-N-methyl-L-tyrosy]-4-phenylpiperazine, enables advanced, selective interrogation of CaMKII-mediated calcium signaling. This article delivers a mechanistic deep dive and strategic comparison, setting a new standard for biochemical assay design.

• Cy3 Goat Anti-Rabbit IgG (H+L) Antibody: Technical Guide

  2026-05-04

  The Cy3 Goat Anti-Rabbit IgG (H+L) Antibody is designed for high-sensitivity detection of rabbit primary antibodies in immunofluorescence, immunohistochemistry, and flow cytometry. This reagent is best suited for applications requiring strong signal amplification and precise localization of target proteins in research workflows. It is not intended for diagnostic or clinical use, and care must be taken to avoid freeze/thaw cycles or exposure to light that could compromise performance.

• EV-Transferred ACLY Drives Immunosuppressive TAM Differentia

  2026-05-03

  This study elucidates how hepatocellular carcinoma (HCC) cells secrete extracellular vesicles (EVs) containing ATP-citrate lyase (ACLY), which monocytes internalize to drive their differentiation into immunosuppressive tumor-associated macrophages (TAMs). The findings highlight a mechanistic link between tumor cell-derived metabolic cues and the establishment of an immune-suppressive microenvironment, suggesting new strategies for immunotherapy in liver cancer.

• Ibrutinib (PCI-32765): Selective BTK Inhibition in B-Cell Mo

  2026-05-02

  Ibrutinib (PCI-32765) is a potent and selective Bruton’s tyrosine kinase (BTK) inhibitor used to dissect B-cell receptor signaling and model B-cell malignancies. Its nanomolar potency, irreversibility, and defined solubility enable reliable in vitro and in vivo research. This article details its mechanism, benchmarks, and protocol considerations for advanced scientific workflows.

• PDK4-IN-1 Hydrochloride: Precision PDK4 Inhibition in Metabo

  2026-05-01

  PDK4-IN-1 hydrochloride empowers researchers to modulate mitochondrial energy metabolism and unravel the role of PDK4 in metabolic, cardiac, and cancer models with exceptional selectivity. This article details optimized workflows, troubleshooting strategies, and the unique mechanistic advantages of this orally active PDK4 inhibitor, drawing on cutting-edge research and practical lab experience.

• Refining In Vitro Drug Response Evaluation in Cancer Researc

  2026-05-01

  Schwartz’s dissertation introduces a dual-metric framework for distinguishing proliferative arrest from cell death in cancer drug screening. This approach improves the interpretation of compounds—including DNA topoisomerase II inhibitors such as Flumequine—in mechanistic and translational research.

14756 records 1/984 page Next 12345 下5页 Last page